The COPD-X Plan
Australian and New Zealand Guidelines
for the management of
Chronic Obstructive Pulmonary Disease 2014
These guidelines have been developed and revised by Lung Foundation Australia and
The Thoracic Society of Australia and New Zealand as part of a national COPD program.
Endorsed by the following organisations according to their respective approved criteria:
The COPD-X Guidelines are the outcome of a joint project of the Thoracic Society of Australia and New Zealand and Lung Foundation Australia. The guidelines aim to effect changes in clinical practice based on sound evidence; and shift the emphasis from a predominant reliance on pharmacological treatment of COPD to a range of interventions which include patient education, self-management of exacerbations and pulmonary rehabilitation.
This Australian and New Zealand guideline is written as a decision support aid for clinicians managing people with established COPD. These include general practitioners and other primary health care clinicians, as well as clinicians managing respiratory patients in the hospital setting. It is regularly updated as new evidence is published.
This document should be cited as:
Michael Abramson, Alan J Crockett, Eli Dabscheck, Peter A Frith, Johnson George, Nicholas Glasgow, Sue Jenkins, Christine McDonald, Vanessa McDonald, David K McKenzie, Richard Wood-Baker, Ian Yang, Nick Zwar, on behalf of Lung Foundation Australia and the Thoracic So ciety of Australia and New Zealand. The COPD-X Plan: Australian and New Zealand Guidelines for the management of Chronic Obstructive Pulmonary Disease V2.38, June 2014.
Originally published as:
David K McKenzie, Peter A Frith, Jonathan G W Burdon and G Ian Town. The COPDX Plan: Australian and New Zealand Guidelines for the management of Chronic Obstructive Pulmonary Disease 2003. MJA 2003 178(6 Suppl 17 Mar): S1-S40
Clinical Practice Update
Michael J Abramson, Alan J Crockett, Peter A Frith and Christine F McDonald. COPDX: an update of guidelines for the management of chronic obstructive pulmonary disease with a review of recent evidence. MJA 2006; 184 (7): 342-345